Incyte (INCY) Retained Earnings (2010 - 2026)
Incyte's (INCY) quarterly Retained Earnings came in at $1.1 billion in Q2 2026, up 316.35% YoY from $264.8 million in Q2 2025, and up 113.25% on a QoQ basis from $517.1 million in Q1 2026.
Incyte (INCY) Retained Earnings (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Retained Earnings data on file, last reported at $1.1 billion in Q2 2026.
- Quarterly Retained Earnings rose 316.35% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 316.35% YoY) and the FY2025 annual result came in at $213.8 million, up 119.92% from the prior year.
- Retained Earnings improved to $1.1 billion in Q2 2026, from $517.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.1 billion in Q2 2026 to a low of -$1.4 billion in Q2 2024.
- A 5-year average of -$322.4 million and a median of -$426.4 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings sank 3030.91% — and 2026, when it jumped 316.35%.
- Tracing INCY's Retained Earnings over 5 years: stood at -$437.2 million in 2022, then surged by 136.68% to $160.4 million in 2023, then slumped by 768.94% to -$1.1 billion in 2024, then soared by 119.92% to $213.8 million in 2025, then jumped by 415.84% to $1.1 billion in 2026.
- The last three Retained Earnings figures came in at $1.1 billion (Q2 2026), $517.1 million (Q1 2026), and $213.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 1.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 517.10 Mn |
| Dec 31, 2025 | 213.77 Mn |
| Sep 30, 2025 | -85.51 Mn |
| Jun 30, 2025 | -509.68 Mn |
| Mar 31, 2025 | -914.68 Mn |
| Dec 31, 2024 | -1.07 Bn |
| Sep 30, 2024 | -1.27 Bn |
| Jun 30, 2024 | -1.38 Bn |
| Mar 31, 2024 | 329.93 Mn |
| Dec 31, 2023 | 160.39 Mn |
| Sep 30, 2023 | -40.69 Mn |
| Jun 30, 2023 | -211.96 Mn |
| Mar 31, 2023 | -415.51 Mn |
| Dec 31, 2022 | -437.21 Mn |
| Sep 30, 2022 | -465.68 Mn |
| Jun 30, 2022 | -578.45 Mn |
| Mar 31, 2022 | -739.88 Mn |
| Dec 31, 2021 | -777.87 Mn |
| Sep 30, 2021 | -1.34 Bn |